Institutional investors hold a majority ownership of ISIS through the 89.49% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2014, these large investors purchased a net $2.0 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIRST TRUST ADVISORS LP Bought 1.6 Million shares of Isis Pharmaceuticals Inc